menu
    • menu

    Find Inclisiran manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 9
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    13

    API Suppliers

    3

    USDMF

    0

    CEP/COS

    0

    JDMF

    0

    EU WC

    2

    KDMF

    3

    NDC API

    0

    VMF

    6

    Listed Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    6

    FDF Dossiers

    1

    FDA Orange Book

    2

    Europe

    1

    Canada

    2

    Australia

    0

    South Africa

    0

    Listed Dossiers

    9PROSPECTS

    39DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    26

    US Patents

    3

    US Exclusivities

    0

    Health Canada Patents

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    1,233

    Regulatory FDF Prices

    NA

    MARKET PLACE

    5

    API

    0

    FDF

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    50

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set

    API SUPPLIERS

    read-more
    read-more
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-moreread-more

    01

    PEGS Boston Summit
    Not Confirmed

    01

    Hangzhou Apextide Biomedical Technol...

    China
    arrow
    PEGS Boston Summit
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 41776

    Submission : 2025-04-15

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    PEGS Boston Summit
    Not Confirmed

    02

    Yangzhou Aurisco Pharmaceutical Co L...

    China
    arrow
    PEGS Boston Summit
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2025-10-23

    Pay. Date : 2025-09-25

    DMF Number : 42095

    Submission : 2025-09-24

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Suzhou Olipharma Co Ltd

    Country

    USDMF

    arrow
    PEGS Boston Summit
    Not Confirmed

    03

    Suzhou Olipharma Co Ltd

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 43518

    Submission : 2026-01-29

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KDMF

    read-more
    read-moreread-more

    01

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    PEGS Boston Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    sodium inclisiran

    Registrant Name : Novartis Korea

    Registration Date : 2026-02-25

    Registration Number : Su196-34-ND

    Manufacturer Name : Novartis Pharma Schweizerhal...

    Manufacturer Address : Rothausstrasse, 4133, Pratteln, Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    ST Pharma

    South Korea
    PEGS Boston Summit
    Not Confirmed
    arrow

    ST Pharma

    South Korea
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag South Korea
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    sodium inclisiran

    Registrant Name : Novartis Korea

    Registration Date : 2024-06-20

    Registration Number : Su196-29-ND

    Manufacturer Name : ST Pharm Co., Ltd.

    Manufacturer Address : 171 Haean-ro, Danwon-gu, Ansan-si, Gyeonggi-do

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    NDC API

    read-more
    read-moreread-more

    01

    Agilent Technologies Inc.

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Agilent Technologies Inc.

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    INCLISIRAN

    NDC Package Code : 70596-1002

    Start Marketing Date : 2021-12-27

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Shanghai Desano Chemical Pharmaceut...

    China
    PEGS Boston Summit
    Not Confirmed
    arrow

    Shanghai Desano Chemical Pharmaceut...

    China
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    INCLISIRAN SODIUM

    NDC Package Code : 42931-712

    Start Marketing Date : 2024-11-26

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    ST Pharm Co., Ltd.

    South Korea
    PEGS Boston Summit
    Not Confirmed
    arrow

    ST Pharm Co., Ltd.

    South Korea
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag South Korea
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    INCLISIRAN SODIUM

    NDC Package Code : 73675-006

    Start Marketing Date : 2025-12-18

    End Marketing Date : 2027-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Suppliers

    read-more
    read-more

    01

    EUROAPI

    France
    arrow
    CPhI North America
    Booth #1525
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Inclisiran

    About the Company : EUROAPI focuses on reinventing active ingredient solutions to sustainably meet the needs of customers and patients worldwide. The company is a leading API player with a portfolio o...

    EUROAPI focuses on reinventing active ingredient solutions to sustainably meet the needs of customers and patients worldwide. The company is a leading API player with a portfolio of around 200 products, covering a wide range of technologies and innovative molecules through CDMO activities. Supported by 3,650 employees, strong R&D capabilities, and six manufacturing sites in Europe, EUROAPI delivers high-quality API manufacturing to customers in more than 80 countries. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    EUROAPI Compnay Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Transo-Pharm USA LLC

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Inclisiran

    About the Company : Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and a...

    Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and acts as a sourcing and regulatory marketing agent for API manufacturers. Transo-Pharm assists with DMF setup, GMP consulting, and regulatory activities, supported by a regulatory team, warehouse facilities, proprietary API process IPs, and laboratory partnerships, with offices in Shanghai, Hong Kong, Singapore, and the US. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Transo Pharm USA Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Omgene Life Sciences Pvt. Ltd

    India
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Inclisiran

    About the Company : Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integ...

    Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Omgene Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Anhui Ribobay Pharmaceutical Co.,Lt...

    China
    PEGS Boston Summit
    Not Confirmed
    arrow

    Anhui Ribobay Pharmaceutical Co.,Lt...

    China
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Inclisiran

    About the Company : Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuz...

    Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuzhou, within the Nanjing metropolitan area, Ribobay Pharmaceutical specializes in the therapeutic oligonucleotides CXO field. This strategic focus aligns with General Biol's broader expansion plans for its CXO business, making Ribobay a crucial component of the company's ventures in this domain.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Gyma Laboratories of America

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Gyma Laboratories of America

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Inclisiran

    About the Company : For more than 60 years, GYMA Laboratories has been the leading and trusted API supplier to the US pharmaceutical industry. We’re proud that many of the pharmaceutical manufacture...

    For more than 60 years, GYMA Laboratories has been the leading and trusted API supplier to the US pharmaceutical industry. We’re proud that many of the pharmaceutical manufacturers who rely on our integrity, expertise, and follow-through have been with us for three, four, and even five decades.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Jiangsu Sinopep Allsino Biopharmace...

    China
    PEGS Boston Summit
    Not Confirmed
    arrow

    Jiangsu Sinopep Allsino Biopharmace...

    China
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Inclisiran

    About the Company : Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and effici...

    Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and efficient manufacturing technologies, Sinopep ensures global compliance with advanced process development. Their CRDMO services span peptides, oligonucleotides, and synthetic conjugates, making them a trusted partner worldwide in pharmaceutical and healthcare solutions.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Early Hospital Initiation of Inclisiran Safety and Efficacy In ACS

    Details:

    Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Acute Coronary Syndrome.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 04, 2025

    blank

    01

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Early Hospital Initiation of Inclisiran Safety and Efficacy In ACS

    Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Acute Coronary Syndrome.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    August 04, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Approves Novartis’ Leqvio For First-Line Twice-Yearly Use

    Details:

    Leqvio (inclisiran) is a siRNA directed to PCSK9 mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

    Study Phase: Approved FDFProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 31, 2025

    blank

    02

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FDA Approves Novartis’ Leqvio For First-Line Twice-Yearly Use

    Details : Leqvio (inclisiran) is a siRNA directed to PCSK9 mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia.

    Product Name : Leqvio

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    July 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention o...

    Details:

    Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.


    Lead Product(s): Inclisiran Sodium,Inclisiran

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Oligonucleotide

    Sponsor: Novartis Pharmaceuticals Corporation | Colorado Prevention Center | Mount Sinai Hospital, New York

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 03, 2025

    blank

    03

    Duke University

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Duke University

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran Sodium,Inclisiran

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation | Colorado Prevention Center | Mount Sinai Hospital, New York

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Pa...

    Details : Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    April 03, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

    Details:

    Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Metabolic Syndrome.


    Lead Product(s): Inclisiran Sodium,Inclisiran

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Oligonucleotide

    Sponsor: Novartis Pharmaceuticals Corporation

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 10, 2025

    blank

    04

    University of California, San Diego

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    University of California, San Diego

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran Sodium,Inclisiran

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

    Details : Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Metabolic Syndrome.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    March 10, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

    Details:

    Pelacarsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atherosclerosis.


    Lead Product(s): Pelacarsen,Inclisiran

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 07, 2025

    blank

    05

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pelacarsen,Inclisiran

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevat...

    Details : Pelacarsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atherosclerosis.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    February 07, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

    Details:

    Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 19, 2024

    blank

    06

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Fami...

    Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    September 19, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

    Details:

    Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heterozygous Familial Hypercholesterolemia.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 19, 2024

    blank

    07

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hyperch...

    Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heterozygous Familial Hypercholesterolemia.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    September 19, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis' Leqvio® Shows Significant LDL-C Lowering As Monotherapy

    Details:

    Leqvio (inclisiran), the first and only approved siRNA indicated in patients with low or moderate risk of developing atherosclerotic cardiovascular disease and not receiving lipid-lowering therapy.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

    Study Phase: Approved FDFProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 28, 2024

    blank

    08

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Novartis' Leqvio® Shows Significant LDL-C Lowering As Monotherapy

    Details : Leqvio (inclisiran), the first and only approved siRNA indicated in patients with low or moderate risk of developing atherosclerotic cardiovascular disease and not receiving lipid-lowering therapy.

    Product Name : Leqvio

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    August 28, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strand

    Details:

    Leqvio (inclisiran), approved in over 80 countries, is the first and only approved Small interfering RNA therapy with a successful synthesis of the antisense strand of this drug.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

    Study Phase: Approved FDFProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 09, 2024

    blank

    09

    EnPlusOne Biosciences

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    EnPlusOne Biosciences

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strand

    Details : Leqvio (inclisiran), approved in over 80 countries, is the first and only approved Small interfering RNA therapy with a successful synthesis of the antisense strand of this drug.

    Product Name : Leqvio

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    July 09, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemi...

    Details:

    Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypercholesterolemia.


    Lead Product(s): Inclisiran,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 26, 2024

    blank

    10

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inclisiran,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients ...

    Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypercholesterolemia.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    April 26, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    PEGS Boston Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    INCLISIRAN SODIUM

    Brand Name : LEQVIO

    Dosage Form : SOLUTION;SUBCUTANEOUS

    Dosage Strength : EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)

    Packaging :

    Approval Date : 2021-12-22

    Application Number : 214012

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    PEGS Boston Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Estonia

    Inclisiran

    Brand Name : Leqvio

    Dosage Form : Solution For Injection

    Dosage Strength : 284mg/1.5ml

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Prescription

    Registration Country : Estonia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    PEGS Boston Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Inclisiran

    Brand Name : Leqvio

    Dosage Form : Solution For Injection

    Dosage Strength : 284mg

    Packaging :

    Approval Date : 09-12-2020

    Application Number : 28106393820

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    PEGS Boston Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : PRESCRIPTION

    Registration Country : Canada

    INCLISIRAN (INCLISIRAN SODIUM)

    Brand Name : LEQVIO

    Dosage Form : SOLUTION

    Dosage Strength : 284MG/1.5ML

    Packaging :

    Approval Date :

    Application Number : 2518376

    Regulatory Info : PRESCRIPTION

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    PEGS Boston Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    inclisiran

    Brand Name : Leqvio

    Dosage Form :

    Dosage Strength :

    Packaging : 1

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    PEGS Boston Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    inclisiran

    Brand Name : Leqvio

    Dosage Form :

    Dosage Strength :

    Packaging : 1

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    APIs

    read-more
    read-more
    india-flag.png
    Inclisiran API needed in India [ENA24034]
    A company that focuses on the manufacturing of various finished formulations is looking for suppliers of Inclisiran API for development purposes. The suppliers must support this enquiry with DMF & CoA.
    15 Sep 2025

    Reply

    15 Sep 2025

    Reply text-arrow

    Reply Comment (2)

    15 Sep 2025

    india-flag.png
    Injectable Grade Inclisiran API needed in India [ENA23425]
    A company that focuses on the development and manufacturing of OSDs, liquids, semi-solids and injectables is looking for suppliers of Injectable Grade Inclisiran API. The initial required quantity is 500 g for development & exhibit batches, later 1 kg - 2 kg for commercial purposes. The suppliers must support this enquiry with CoA.
    04 Jul 2025

    Reply

    04 Jul 2025

    Reply text-arrow

    Reply Comment (1)

    04 Jul 2025

    Oman.png
    Inclisiran (1 g) API needed in Oman [ENA20652]
    A company that focuses on development of various vaccine and medicine in areas of oncology, immunology and gene therapy is looking for suppliers of Inclisiran (1 g) API for development purposes. The suppliers must support this enquiry with GMP & CoA.
    25 Sep 2024

    Reply

    25 Sep 2024

    Reply text-arrow

    Reply Comment (5)

    25 Sep 2024

    india-flag.png
    Inclisiran Sodium API needed in India [ENA18923]
    A company that focuses in research, development and manufacturing of complex generic and novel innovative pharmaceutical products such as oral solid dosage forms, injectables and nutraceuticals is looking for suppliers of Inclisiran Sodium API for development purposes. The required quantity is MOQ. The suppliers must support this enquiry with CoA.
    18 Jan 2024

    Reply

    18 Jan 2024

    Reply text-arrow

    Reply Comment (3)

    18 Jan 2024

    Egypt.png
    Inclisiran (200 g) API needed in Egypt [ENA16468]
    A company that deals in various pharmaceutical products is looking for suppliers of Inclisiran (200 g) API for development purposes. The suppliers must support this enquiry with CoA.
    24 Feb 2023

    Reply

    24 Feb 2023

    Reply text-arrow

    Reply Comment (8)

    24 Feb 2023

    PharmaCompass
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    US Patents

    read-more
    read-more

    01

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2027-12-29

    INCLISIRAN SODIUM

    US Patent Number : 8222222

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-12-29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2036-08-25

    INCLISIRAN SODIUM

    US Patent Number : 10851377

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 214012

    Patent Use Code : U-4414

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2036-08-25

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2028-12-04

    INCLISIRAN SODIUM

    US Patent Number : 9370582

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code : U-4413

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2028-12-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2029-12-12

    INCLISIRAN SODIUM

    US Patent Number : 8106022

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2029-12-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2028-08-24

    INCLISIRAN SODIUM

    US Patent Number : 10131907

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code : U-4413

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2028-08-24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2027-12-29

    INCLISIRAN SODIUM

    US Patent Number : 8222222

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 214012

    Patent Use Code : U-4413

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-12-29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2034-08-18

    INCLISIRAN SODIUM

    US Patent Number : 10125369

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2034-08-18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2028-12-04

    INCLISIRAN SODIUM

    US Patent Number : 9370582

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 214012

    Patent Use Code : U-4414

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2028-12-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2027-12-29

    INCLISIRAN SODIUM

    US Patent Number : 8222222

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 214012

    Patent Use Code : U-4414

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-12-29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2036-08-25

    INCLISIRAN SODIUM

    US Patent Number : 10851377

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 214012

    Patent Use Code : U-4249

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2036-08-25

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    US Exclusivities

    read-more
    read-more

    NOVARTIS

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    INCLISIRAN SODIUM

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    I-985
    2029-02-12
    214012
    1
    blank

    01

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    INCLISIRAN SODIUM

    Exclusivity Code : I-985

    Exclusivity Expiration Date : 2029-02-12

    Application Number : 214012

    Product Number : 1

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    NOVARTIS

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    INCLISIRAN SODIUM

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    NCE
    2026-12-22
    214012
    1
    blank

    02

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    INCLISIRAN SODIUM

    Exclusivity Code : NCE

    Exclusivity Expiration Date : 2026-12-22

    Application Number : 214012

    Product Number : 1

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    NOVARTIS

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    INCLISIRAN SODIUM

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    NPP
    2029-02-12
    214012
    1
    blank

    03

    NOVARTIS

    INCLISIRAN SODIUM

    arrow
    PEGS Boston Summit
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    INCLISIRAN SODIUM

    Exclusivity Code : NPP

    Exclusivity Expiration Date : 2029-02-12

    Application Number : 214012

    Product Number : 1

    Exclusivity Details :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search